Amgen is cutting 180 R&D jobs and exiting neuroscience R&D. Novartis receives a clinical hold. IVERIC up 57% YTD after phase 2 data. Looking for …
Link to Full Article: Read Here
Oct 31, 2019 | News Stories
Amgen is cutting 180 R&D jobs and exiting neuroscience R&D. Novartis receives a clinical hold. IVERIC up 57% YTD after phase 2 data. Looking for …
Link to Full Article: Read Here